{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T22:39:50Z","timestamp":1790375990823,"version":"4.1.0"},"reference-count":14,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.lungcan.2019.06.015","type":"journal-article","created":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T11:15:53Z","timestamp":1562670953000},"page":"29-32","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"special_numbering":"C","title":["Fatal adverse events in two thymoma patients treated with anti-PD-1 immune check point inhibitor and literature review"],"prefix":"10.1016","volume":"135","author":[{"given":"Thomopoulou","family":"Konstantina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rounis","family":"Konstantinos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8430-7565","authenticated-orcid":false,"given":"Koutsopoulos","family":"Anastasios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mala","family":"Anastasia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lagoudaki","family":"Eleni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sougklakos","family":"Ioannis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agelaki","family":"Sofia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mavroudis","family":"Dimitris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.lungcan.2019.06.015_bib0005","series-title":"World Health Organization Classification of Tumors of the Lung, Pleura, Thymus and Heart","article-title":"WHO histological classification of tumors of the thymus","year":"2015"},{"issue":"Suppl 5","key":"10.1016\/j.lungcan.2019.06.015_bib0010","doi-asserted-by":"crossref","first-page":"v40","DOI":"10.1093\/annonc\/mdv277","article-title":"ESMO guidelines committee. Thymic epithelial tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26","author":"Girard","year":"2015","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2019.06.015_bib0015","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","article-title":"Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy","volume":"60","author":"Zimmer","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2019.06.015_bib0020","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejca.2017.05.041","article-title":"Myasthenia gravis: an emerging toxicity of immune checkpoint inhibitors","volume":"82","author":"Makariousa","year":"2017","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.lungcan.2019.06.015_bib0025","article-title":"A phase II study of pembrolizumab for patients with previously treated advanced thymic epithelial tumor","volume":"35","author":"Chol","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2019.06.015_bib0030","doi-asserted-by":"crossref","first-page":"S130","DOI":"10.1016\/j.jtho.2016.11.333","article-title":"OA18.03:safety and clinical activity of avelumab(MSB0010718C;anti-PDL1) in patients with advanced thymic epithelial tumors","volume":"12","author":"Rajan","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.lungcan.2019.06.015_bib0035","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Gaccione","year":"2018","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.lungcan.2019.06.015_bib0040","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/nri798","article-title":"T-cell development and the CD4\u2013CD8 lineage decision","volume":"2","author":"Germain","year":"2002","journal-title":"Nat. Rev. Immunol."},{"issue":"3","key":"10.1016\/j.lungcan.2019.06.015_bib0045","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/cmi.2010.74","article-title":"Thymoma and autoimmunity","volume":"8","author":"Shelly","year":"2011","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.lungcan.2019.06.015_bib0050","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1093\/ejcts\/ezs529","article-title":"Clinicopathological features of thymic carcinomas and the impact of histopathological agreement on prognostical studies","volume":"43","author":"Roden","year":"2013","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"10.1016\/j.lungcan.2019.06.015_bib0055","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1111\/j.1365-2559.2008.03088.x","article-title":"Interobserver variation in the classification of thymic tumors \u2013 a multicentre study using the WHO classification system","volume":"53","author":"Verghese","year":"2008","journal-title":"Histopathology"},{"issue":"1","key":"10.1016\/j.lungcan.2019.06.015_bib0060","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1600-065X.2010.00923.x","article-title":"The PD-1 pathway in tolerance and autoimmunity","volume":"236","author":"Francisco","year":"2010","journal-title":"Immunol. Rev."},{"issue":"September (11)","key":"10.1016\/j.lungcan.2019.06.015_bib0065","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","article-title":"Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan","volume":"89","author":"Suzuki","year":"2017","journal-title":"Neurology"},{"issue":"April (14)","key":"10.1016\/j.lungcan.2019.06.015_bib0070","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1212\/WNL.0000000000007235","article-title":"Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies","volume":"92","author":"Johansen","year":"2019","journal-title":"Neurology"}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500219305082?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500219305082?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T12:31:29Z","timestamp":1759235489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500219305082"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":14,"alternative-id":["S0169500219305082"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2019.06.015","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fatal adverse events in two thymoma patients treated with anti-PD-1 immune check point inhibitor and literature review","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2019.06.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}